Live Analyst Rating Changes 1505 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Sami Corwin
WB
Sami Corwin
William Blair
Wall Street Analyst
★★★★☆
#438
on 13Foresight · ranked by our own returns
56%
Success Rate
+35.2%
Average Return
15 of 27 calls profitable · +29.5% vs benchmark
📈 Across the calls we could measure, roughly 56% of Sami Corwin's ratings turned a profit when each position was held for 1 year — averaging +35.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

136 Buy 36 Hold 0 Sell
Sami's Stock Coverage 23 ratings · 2026-06-18
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
TYRA
Tyra Bioscience
 Jun 10, 2026 BUY Strong Buy
+55.7% avg upside
17 analysts
 — +0.7%
NGNE
Neurogene
 Jun 08, 2026 BUY Buy
+58.4% avg upside
23 analysts
 — ·
ZVRA
Zevra Therapeutics
 Jun 08, 2026 BUY Strong Buy
+88.2% avg upside
15 analysts
 — ·
CRSP
Crispr Therapeutics AG
 Jun 04, 2026 BUY Buy
+41.5% avg upside
41 analysts
 — -8.7%
CABA
Cabaletta Bio
 Jun 03, 2026 BUY Strong Buy
+388.8% avg upside
16 analysts
 — ·
KYTX
Kyverna Therapeutics, Inc.
 Jun 03, 2026 BUY Strong Buy
+239.9% avg upside
7 analysts
 — +2.8%
KRYS
Krystal Biotech
 May 18, 2026 BUY Strong Buy
-27.6% avg upside
19 analysts
 — +17.1%
ALLO
Allogene Therapeutics
 May 14, 2026 BUY Strong Buy
+673.3% avg upside
28 analysts
 — -11.2%
SLDB
Solid Biosciences
 May 13, 2026 BUY Strong Buy
+112.8% avg upside
23 analysts
 — -6.2%
BEAM
Beam Therapeutics
 May 07, 2026 BUY Strong Buy
+57.5% avg upside
25 analysts
$32.00
4.45% Downside
 -6.6%
AKTS
Aktis Oncology, Inc.
 May 02, 2026 BUY Strong Buy
+32.6% avg upside
8 analysts
$18.75
21.97% Downside
 ·
RCKT
Rocket Pharmaceuticals
 Feb 26, 2026 BUY Buy
+418.9% avg upside
29 analysts
 — -34.7%
SRPT
Sarepta Therapeutics
 Feb 26, 2026 HOLD Buy
+251.8% avg upside
49 analysts
 — -9.7%
BMRN
BioMarin Pharmaceutical
 Feb 24, 2026 HOLD Strong Buy
+71.7% avg upside
52 analysts
 — -12.1%
PTCT
PTC Therapeutics
 Feb 20, 2026 BUY Strong Buy
-1.0% avg upside
29 analysts
 — +11.1%
RARE
Ultragenyx Pharmaceutical
 Feb 13, 2026 BUY Strong Buy
+144.1% avg upside
36 analysts
 — +12.6%
QURE
uniQure
 Feb 06, 2026 HOLD Strong Buy
+2.0% avg upside
29 analysts
 — -3.6%
TNYA
Tenaya Therapeutics
 Jan 09, 2026 BUY Strong Buy
+1328.2% avg upside
11 analysts
 — +13.2%
LEGN
Legend Biotech
 Nov 12, 2025 HOLD Strong Buy
+115.9% avg upside
27 analysts
 — +15.1%
NKTX
Nkarta
 Nov 11, 2025 HOLD Strong Buy
+606.1% avg upside
15 analysts
 — +31.3%
IPSC
Century Therapeutics
 Aug 29, 2025 HOLD Strong Buy
+136.7% avg upside
11 analysts
 — +369.5%
MESO
Mesoblast
 Dec 22, 2023 HOLD Strong Buy
+76.4% avg upside
14 analysts
 — +577.3%
TSHA
Taysha Gene Therapies
 Feb 01, 2023 BUY Strong Buy
+108.8% avg upside
21 analysts
 — +28.9%
🔒 18 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Sami Corwin — Frequently Asked Questions
How accurate are Sami Corwin's stock ratings?
Based on the calls 13Foresight could measure, about 56% of Sami's ratings were profitable over a one-year hold, with an average return of +35.2% per rating, or +29.5% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Sami ranked on 13Foresight?
Sami Corwin is currently ranked #438 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Sami cover?
Sami most recently has ratings on TYRA, NGNE, ZVRA, CRSP, CABA, KYTX, KRYS, ALLO, SLDB, BEAM, AKTS, RCKT and 11 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.